ESTEVE positions itself in the Portuguese ophthalmology market, transferring its more than fifty years of experience in the field of ophthalmology, one of the pillars of the international pharmaceutical company.

It will be available in two formulations: Aquoral, for mild or environmental dry eye, and Aquoral Forte, for moderate and severe dry eye.

ESTEVE, the international pharmaceutical company, launches Aquoral, its line of products based on hyaluronic acid and indicated for the treatment of mild to severe dry eyes, in the Portuguese market. The company continues its expansion and its mission to provide innovative products that improve the health and quality of life of its patients.

Gonçalo Mello-Barreto, Commercial Director of ESTEVE Portugal, underlines the pharmaceutical company’s commitment to putting the focus on patients. ''This launch is in line with ESTEVE's goal of improving people's lives. Portugal is a strategic market with a potential growth''.

''Aquoral's success in other markets lies both in the quality of the product and in our efforts to innovate and offer presentations tailored to people’s everyday needs'', he adds.

ESTEVE has more than 50 years of experience in the field of Ophthalmology and offers different products for pathologies of the ocular surface, glaucoma and retina.

ESTEVE, a responsible and sustainable company

The company has been at the service of health for more than 90 years. Innovation and people's well-being are key to its corporate strategy which in turn is built on its core values: transparency, accountability and the importance of people.

As one of the first Spanish companies to sign up to the United Nations Global Compact in 2002, ESTEVE is committed to achieving the Sustainable Development Goals defined in the 2030 Agenda. Its sustainability policy is based on three pillars: caring for people, caring for the environment, and caring for our business.